Using advanced imaging to detect early brain changes in a rare genetic disorder
Leveraging Myelin-Sensitive Imaging to Predict Early Lesion Pathogenesis in Cerebral Adrenoleukodystrophy
This study is looking at a serious brain condition called X-linked Adrenoleukodystrophy (ALD) that mainly affects kids, and it aims to find early signs of brain damage using special imaging techniques so that doctors can start treatment sooner and help improve kids' health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hugo W. Moser Res Inst Kennedy Krieger NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10873934 on NIH RePORTER |
What this research studies
This research focuses on X-linked Adrenoleukodystrophy (ALD), a severe neurological condition that primarily affects children. The study aims to utilize advanced imaging techniques, specifically Diffusion Tensor Imaging (DTI) and Myelin Water Fraction (MWF) Imaging, to identify early signs of brain lesions before significant neurological symptoms occur. By detecting these changes early, the research hopes to extend the treatment window for patients, allowing for timely interventions that could improve outcomes. The approach involves monitoring changes in myelin and brain structure to better understand the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include children diagnosed with X-linked Adrenoleukodystrophy, particularly those at risk of developing cerebral ALD.
Not a fit: Patients with other neurological disorders or those who do not have X-linked Adrenoleukodystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and treatment of cerebral ALD, potentially improving neurological outcomes for affected children.
How similar studies have performed: Previous research has shown promise in using advanced imaging techniques to detect early neurological changes in other conditions, suggesting potential success for this novel approach in ALD.
Where this research is happening
Baltimore, United States
- Hugo W. Moser Res Inst Kennedy Krieger — Baltimore, United States (Active)
Researchers
- Principal investigator: Mallack, Eric — Hugo W. Moser Res Inst Kennedy Krieger
- Study coordinator: Mallack, Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.